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EVALUATION OF PULMONARY 
MANIFESTATIONS IN HEMATOLOGICAL 
MALIGNANCIES 
Background: Leukemias and lymphomas are a diverse group of 
disorders in which various pulmonary manifestations are noted. These 
pulmonary manifestations are dependent upon multiple factors, 
including the type of leukemia, the nature and time course of treatment, 
and presence or absence of significant neutropenia and 
thrombocytopenia. Many of the pulmonary abnormalities are not due to 
the leukemia itself, but are caused by the patient’s immunocompromised 
status, medications, or a complicating medical illness. Not many studies 
are available regarding pulmonary manifestations in hematological 
malignancies. Hence this study was done to analyze the various 
pulmonary manifestations in these disorders.  
Aim: To evaluate the pulmonary manifestations of patients with 
hematological malignancies in a tertiary care Institution 
Method: Patients diagnosed with hematological malignancies having 
respiratory manifestations or with chest radiological abnormalities were 
subjected to various diagnostic tests including CBC, RFT, RBS, LFT, 
sputum AFB, sputum gram stain, sputum nontuberculous culture, 
sputum fungal smear& culture, sputum cytology for malignant cells, 
chest X-ray, CT/HRCT chest, pleural fluid analysis. 
Results: we included 124 patients (male/female: 42/82) with 
hematological malignancies (51 Acute Myeloid leukemia, 8 Chronic 
Myeloid leukemia, 47 Acute lymphoblastic leukemia, 17 Chronic 
lymphoid leukemia and one Hodgkin lymphoma) who presented with 
respiratory symptoms and signs during examination. 47% of the patients 
had an absolute neutrophil count lower than 1000 cells/µl. out of 124 
patients, 60 patients had no parenchymal infiltrates, 6 patients had 
pleural effusion, 58 patients had parenchymal infiltrates (31 focal/27 
diffuse) were identified. An etiological diagnosis was obtained in 109 
(88%) of the 124 patients. 60 (48%) patients had Upper respiratory tract 
infection and acute bronchitis, 28 (22.58%) had bacterial pneumonia, 
14(11%) patients had fungal pneumonia, 6 (5%) patients had exudative 
pleural effusion and one patient was infected with mycobacterium 
tuberculosis. Bacterial pneumonia predominantly presented as focal 
infiltrates and fungal pneumonia as diffuse infiltrates. The sputum 
culture reports were positive more for bacterial organisms followed by 
fungal organisms. Among them Pseudomonas aeroginosa was the 
predominant organism, followed by Klebsiella pneumonia and 
Aspergillus fumigates.  
CONCLUSION: Pulmonary infections are common cause for 
increased morbidity and mortality in patients with hematological 
malignancies. Upper respiratory tract infection and acute bronchitis are 
the most common associated respiratory diagnosis in patients with 
hematological malignancies. Neutropenia is the major factor in 
determining the development of pulmonary infections. Bacterial 
pneumonia predominantly present as focal infiltrates and fungal 
pneumonia as diffuse infiltrates. Pulmonary infections are 
predominantly caused by gram-negative bacteria (Pseudomonas 
aeroginosa & Klebsiella pneumonia) followed by fungal (Aspergillus 
fumigates) organisms. 
KEY WORDS: hematological malignancies, neutropenia, 
parenchymal infiltrate,  pulmonary infection. 
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INTRODUCTION 
  Leukemias and lymphomas are a diverse group of disorders.         
        Myeloid neoplasms are heterogeneous group of disease which has 
an origin in a progenitor cell that normally gives rise to terminally 
differentiated cells of myeloid series (erythrocytes, granulocytes, 
monocytes and platelets). Three categories of myeloid neoplasia are 
recognized, they are:  
1. Acute myelogenous leukemias, in which immature progenitor 
cells accumulate in the bone marrow 
2. Myelodysplastic syndrome associated with ineffective 
hematopoiesis and leads to peripheral blood cytopenias 
3. Chronic myeloproliferative disorders in which increased 
production of one or more terminal differentiated myeloid 
elements usually leads to an elevation of peripheral counts.            
          Lymphoid neoplasms are a diverse group of entities, in which 
the neoplastic cells closely resembles that of a particular stage of 
normal lymphocyte differentiation. Lymphomas can be divided into 
Hodgkin lymphoma and the non-Hodgkin lymphoma (NHL).  
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          Acute lymphoblastic leukemia/lymphoma (ALL) includes a 
group of neoplasms composed of immature precursor B (pre-B) or T 
(pre-T) lymphocytes. Chronic lymphocytic leukemia (CLL) is the most 
common variety of leukemia, accounting for 30% cases, which 
composed of mature B lymphocytes.                                      
             Pulmonary complications are common in patients with any of 
the hematological malignancies. These pulmonary manifestations are 
dependent upon multiple factors, including the type of leukemia, 
absence of significant neutropenia and thrombocytopenia and the 
nature and time course of treatment. Many of the pulmonary 
abnormalities are not due to the leukemia itself, but are caused by the 
patient‟s immunocompromised status, chemotherapy and radiotherapy, 
or a complicating medical illness. 
              In leukemia, the true incidence of pulmonary complications 
is difficult to assess because most articles reported are selected for 
patients with specific pulmonary complications or particular 
leukemias. Moreover, the incidence of pulmonary manifestations 
varies over a wide range, depending upon whether symptoms, sputum 
analysis, chest radiographs, CT chest, bronchoalveolar lavage or 
histopathological findings alone are used as the index of disease. 
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          In patients with hematological neoplasms, the most common 
pulmonary complication is infections with bacterial or opportunistic 
pathogens. Pleural effusions in hematological malignancies may occur 
as an isolated finding or associated with parenchymal abnormalities, 
occur usually in patients with hematological malignancies. The causes 
for pleural effusions are pleural involvement by neoplasm, infection, 
lymphatic obstruction, fluid overload and radiation or chemotherapy 
effects.  
        Not many studies are available regarding pulmonary 
manifestations in hematological malignancies. Hence this study was 
done to analyze the various pulmonary manifestations in these 
disorders. 
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AIM OF THE STUDY 
To evaluate the pulmonary manifestations of patients with 
hematological malignancies in a tertiary care Institution. 
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REVIEW OF THE LITERATURE 
 
        The primary mode of search for articles was through internet 
database like „pub med‟, “Google scholar” and hand search of articles. 
The general search items were „hematological malignancies‟, 
„pulmonary complications‟, „pneumonia‟, „neutropenia‟ and 
„radiological features‟. The articles included in this review were those 
that primarily dealt with pulmonary complications of leukemia, non-
invasive diagnostic approach in non-immunocompromised patients with 
pulmonary infiltrates, those dealt with pleural effusion in hematological 
malignancies, tuberculosis in leukemia & lymphoma, fungal infections 
in hematological malignancies, febrile neutropenia and those dealt with 
pulmonary parenchymal infiltrates in neutropenia with hematological 
malignancies during chemotherapy. Articles in languages other than 
English for lack of comprehension were excluded. 
          Leukemias and lymphomas are a heterogeneous group of 
neoplasms in which various pulmonary manifestations are noted. These 
pulmonary manifestations are not only dependent upon the type of 
leukemia, and also type of treatment, and presence or absence of 
significant neutropenia and thrombocytopenia. Pulmonary 
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complications in hematological malignancies are not due to the primary 
neoplasm itself, but are caused by the patient‟s immunocompromised 
status, chemotherapy, or co morbidities like diabetes mellitus, chronic 
renal failure, etc... 
CLASSIFICATION OF ACUTE LEUKEMIA (AL) & 
MYELODYSPLASTIC SYNDROME (MDS) 
 Acute lymphoid leukemia 
 Precursor-B cell lymphoblastic leukemia/lymphoma 
 Precursor-T cell lymphoblastic leukemia/lymphoma 
 Burkitt lymphoma/ leukemia 
 MDS 
 Acute myeloid leukemia (AML) 
 Acute leukemia (AL) of ambiguous lineage 
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WORLD HEALTH ORGANISATION (WHO) 
CLASSIFICATION OF MALIGNANT LYMPHOMAS 
B-CELL NEOPLASMS 
       PRECURSOR B-CELL NEOPLASM 
 Precursor-B cell lymphoblastic leukemia/lymphoma 
      
MATURE B-CELL NEOPLASM 
 Follicular lymphoma 
 Chronic lymphocytic leukemia/ small lymphocytic 
leukemia 
 Lymphoplasmocytic lymphoma 
 Mantle cell lymphoma 
 Nodal marginal zone B-cell lymphoma 
 Splenic marginal zone B-cell lymphoma 
 Extra nodal marginal zone B-cell lymphoma of mucosa 
associated lymphoid tissue 
 Diffuse large B-cell lymphoma 
 Mediastinal (thymic) large B-cell lymphoma 
 Intravascular large B-cell lymphoma 
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 Primary effusion lymphoma 
 Burkitt lymphoma 
 
T-CELL AND NK-CELL NEOPLASM 
         PRECURSOR T-CELL NEOPLASM 
 Precursor-B cell lymphoblastic leukemia/lymphoma 
 MATURE T-CELL AND NK-CELL LYMPHOMA 
 Peripheral T-cell lymphoma, unspecified 
 Angioimmunoblastic T-cell lymphoma 
 Anaplastic large cell lymphoma 
 Adult T-cell leukemia/ lymphoma 
 Hepatosplenic T-cell lymphoma 
 Subcutaneous panniclitis-like T-cell lymphoma 
 Enteropathy- type T-cell lymphoma 
 Mycosis fungoides/sezary syndrome 
 Extra nodal NK/T-cell lymphoma, nasal type 
 Aggressive NK-cell leukemia 
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HODGKIN LYMPHOMAS 
CLASSICAL 
 Mixed cellularity 
 Lymphocyte-rich 
 Nodular sclerosis 
 Lymphocyte-depleted 
NODULAR LYMPHOCYTE-PREDOMINANT  
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ACUTE MYELOID LEUKEMIA (AML) 
          Acute myeloid leukemia (AML) refers to a group of myeloid 
leukemias that have clinical similarities and distinct morphologic, 
cytogenic, immunophenotypic, and molecular features.  
         AML is more common in adults, but may occur at any age, with 
increased frequency as age advances. Clinical features of Acute 
myeloid leukemia are similar at all age and are due to the replacement 
or suppression of normal marrow components, by malignant blasts, 
usually resulting in impaired hematopoiesis manifested by cytopenias.  
          In Acute myeloid leukemia, the malignant cells are a blast that 
most often shows myeloid or monocytic differentiation. The myeloid 
blast cell can be identified by the presence of Auer rods or by Sudan 
black, Chloroacetate esterase, Myeloperoxidase (MPO), or Non specific 
esterase positivity on cytochemical stains. In addition to these findings, 
flow cytometry is used to classify acute myeloid leukemia based on the 
presence of lymphoid and myeloid antigens. 
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ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 
       Acute lymphoblastic leukemia (ALL) is a malignant disease that 
originates from a single B- or T- lymphocyte progenitor. Proliferation 
and infiltration of malignant cells in the bone marrow result in 
suppression of hematopoiesis and, leads to fall in counts of granulocyte, 
erythrocyte and platelets. 
          Acute lymphoblastic leukemia (ALL) is predominantly occurs in 
children and young adults. The etiology of Acute lymphoblastic 
leukemia in adults most of the cases is uncertain. ALL is unlikely in 
middle-aged adults but increases in incidence in the elderly.  
          Acute lymphoblastic leukemia is a hematological malignancy that 
is rapidly fatal if untreated.  
         Environmental exposures, smoking, and exposure to agricultural 
chemicals might increase the risk of developing ALL in an adult.   
Blast cells in Acute lymphoblastic leukemia is negative for 
Myeloperoxidase (MPO), instead of which positive for Periodic acid 
shiff (PAS). 
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CHRONIC MYELOID LEUKEMIA (CML) 
        Chronic myeloid leukemia is the most common of the 
myeloproliferative disorders.  
         It can occur at any age, although it is unlikely in children. The 
average age at diagnosis is 50 to 60 years. CML is more common in 
males when compare to females. 
          Chronic myeloid leukemia is defined by the presence of the 
Philadelphia chromosome or molecular genetics evidence of the 
BCR/ABL fusion product. Chronic myeloid leukemia is primarily a 
proliferation and accumulation of granulocytic cells. 
           The peripheral blood features are those of a increase in leukocyte 
count with granulocytes at all stage of maturation, increased number of 
myelocytes and metamyelocytes, Eosinophilia, Absolute monocytosis, 
Basophilia, and elevated level of platelets. The bone marrow is 
characterized by marked hypercellularity with a cellularity approaching 
100%. 
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CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 
      Chronic lymphocytic leukemia is one of the most common type of 
leukemia in western countries. This is an uncommon neoplasm in Asia. 
CLL is more common in men than in women. The etiological factors 
for CLL are unknown in most of cases.  
      Chronic lymphocytic leukemia is a malignancy of small round 
CD5+ B-cells. 
      CLL is the word used to describe the disorder when lymph node 
involvement is the predominant feature.  
       Usually, these lymphomas most commonly present in elderly 
patients with a leukemic phase and generalized lymphadenopathy on 
physical examination. Bone marrow involvement in CLL is often 
extensive. CLL is characterized by the proliferation and accumulation 
of mature-appearing lymphocytes in the marrow, blood, lymph nodes, 
and spleen. 
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HODGKIN LYMPHOMA (HL) 
       Hodgkin lymphoma, in its simplest pathology defined as a 
neoplasm of Reed-Sternberg cells and RS cell variants that are usually 
associated with inflammatory response that often predominate the 
morphologic picture.   
        Hodgkin lymphoma clinically presents as solitary or generalized 
lymphadenopathy. Hodgkin lymphoma most commonly occurs in males 
than females. A bimodal distribution of age at diagnosis has been 
observed in Hodgkin lymphoma, with one peak incidence occurring in 
patients in their twenties and again in those in their eighties.  
        Classic Hodgkin lymphoma is a malignant disorder of lymphoid 
tissue, commonly originated from germinal center B cells. Classic HL 
accounts for 95% of cases. 
        Classical variety contains four histologic subtypes and they are 
nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-
depleted. Four histologic subtypes are distinguished on the basis of 
morphologic appearance and relative proportion of Reed-Sternberg 
cells, lymphocytes, and fibrosis.  
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           Nodular lymphocyte-predominant represents the other major 
category of Hodgkin lymphoma. 
 
PULMONARY COMPLICATIONS IN PERSONS WITH 
LEUKEMIAS AND LYMPHOMAS 
 Infection 
 Involvement of malignant blast cells 
                             Stasis of malignant cells 
                             Blast cell lysis 
                             Hyperleukocytic reaction 
  Hemorrhage 
 Complication of chemotherapy 
 Alveolar proteinosis 
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PULMONARY INFECTIONS IN HEMATOLOGICAL 
MALIGNANCIES 
         Most common cause for morbidity and mortality in patients with 
leukemias and lymphomas are infection. Chest is the commonest site of 
infection in those with hematological neoplasm (1).  
           In patients with leukemias and lymphomas, pulmonary infiltrates 
seen on radiological investigations are generally considered to be of 
infective etiology. In presence of pulmonary infiltrates with fever, such 
patients are treated on Empirical antibiotics along with antifungal 
agents. In most of patients these pulmonary infiltrates persists in spite 
of empirical treatment, and the cause remains obscure.   
           Specific diagnosis and institution of specific treatment in this 
group of patients promptly would be very critical to decrease the 
mortality and morbidity in patients with hematological malignancies 
(2). 
          Patients with hematological malignancies, especially acute 
leukemia have increased risk of severe infection with gram-negative 
bacterial organisms as a result of quantitative or qualitative neutropenia. 
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          In Chronic lymphocytic leukemia and multiple myeloma, patients 
are susceptible to bacterial infections from Staphylococci and 
streptococci.     
          In contrast to that, patients from lymphoma have defect in their 
cellular immune system that results in increased risk of viral and fungal 
infections. In patients with lymphoma therapeutic interventions such as 
corticosteroids, cytotoxic chemotherapy and radiation also cause defect 
in the host defense (3). 
            A  Rano et al in his study recommended using non-invasive 
investigations as a initial step in the evaluation and management of 
pulmonary infiltrates in patients with immunocompromised status, 
especially those with hematological malignancies. These investigations 
include blood and sputum culture. In 44% of the cases use of non-
invasive technique provides the diagnosis and constitutes a good 
alternative for a bronchoscopic investigation (4).  
          S Ewig et al quoted in his article as principle reason for 
pulmonary abnormalities and hospitalization in those with 
hematological malignancies was infection (5).  
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          Gerald P Bodey et al in his study concluded that in 34% of the 
episode of infections were caused by pneumonia (6). Sarah P 
Georgiadou et al in their study found that pulmonary infections were 
more common in patients with acute leukemias (36% AML & 12% 
ALL) (7). 
SPECTRUM OF MICROBIOLOGICAL PATHOGENS IN 
HEMATOLOGICAL MALIGNANCIES. 
            Over the last four decades there has been a marked change in 
the pathogens producing infections in immunocompromised patients, 
especially those with hematological malignancies. 
           In the early 1950s and 1960s among the bacterial organisms 
Staphylococcus aureus was the most common isolate in persons with 
hematological malignancies (8). With the increase in use of beta 
lactamase resistant antistaphylococcal pencillins in treatment, leads to 
emergence of gram-negative bacilli as the common cause for infection, 
especially with pseudomonas aeroginosa, Klebsiella pneumoniae and 
Escherichia coli.  
           Since the 1980s, several studies have demonstrated a shift in the 
etiology of bacterial infections from a predominance of gram-negative 
pathogens to gram-positive cocci (3). 
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            Fungal infections are more common, especially in patients with 
prolonged & severe neutropenia and who receive prolonged courses of 
antibiotics (9). The most frequent isolates among fungal pathogens are 
Aspergillus species, Candida species and C.neoformans. 
            Jagarlamudi R et al in his study says that bacterial pneumonias 
in patients with hematological malignancies were commonly caused by 
gram-positive pathogens (52.8%) than gram-negative pathogens 
(42.8%) (10).  
           S Shawgi et al founded that bacterial pneumonias were most 
commonly caused by gram-negative organisms in his study (2). 
            Baladuci and associates documented that, 193 patients with 
hematological malignancies were affected by infection, among which 
50% of infection were occurred in respiratory tract. In these group of 
patients Pseudomonas aeroginosa, Escherichia coli, Klebsiella 
pneumoniae, and Staphylococcus aureus were the frequent cause of 
infection.. Other causes like Fungi (Candida, Aspergillus) and Virus   
are less frequent organisms (11). 
             A Rano et al in his study says that Staphylococcus aureus, and 
gram-negative bacilli mainly Pseudomonas aeroginosa were the most 
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frequent cause for infections in respiratory tract. Fungal organisms, 
especially Aspergillus species represents the second most frequent 
infectious cause of pulmonary infiltrates (4). Although evidence of 
tissue invasion by fungal organism has classically been required to 
confirm the diagnosis of fungal infections, the presence of Aspergillus 
species in sputum or bronchial lavage culture should be considered 
indicative of invasive fungal disease until proved otherwise and 
warrants institution of specific anti fungal therapy (12). 
            S Ewig et al documented that pneumonia was most frequently 
caused by bacterial organisms followed by fungal organisms. In 
bacterial pneumonia Pseudomonas aeroginosa was the most common 
pathogen, in fungal pneumonia Candida species was the most common 
pathogen (5). 
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 Jain P et al in his study viewed 104 immunocompromised 
patients with pulmonary infiltrates, among them 49% of patients had 
bacterial infection, 26% of patients had viral infection, 21% of patients 
had fungal infection and 4% infections with P.jirovecii. The most 
common organism identified with those bacterial pneumonias was 
Pseudomonas aeroginosa and Staphylococcus aureus followed by 
Escherichia coli. Aspergillus species is the common cause for fungal 
infection in this study (13). 
          Santiago Ewig et al in his study says that gram-positive 
organisms accounted for 52% of respiratory tract infection, gram 
negative pathogens for 36% of respiratory tract infection, and fungal 
organisms for 8% of respiratory tract infection (14). 
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NEUTROPENIA 
            Neutropenia is defined as an absolute neutrophil count 
(polymorphonuclear cells plus band forms) of 1000/µl or less. 
            Neutropenia, resulting from the effect of cytotoxic 
chemotherapy is the most common risk factor for severe bacterial and 
fungal infections in hematological malignancies. The degree of 
Neutropenia either as a consequence of hematological malignancy or 
chemotherapy is directly related to the incidence of serious bacterial 
and fungal pneumonias. 
           There is a significant increase in the incidence of serious 
bacterial & fungal infection once Absolute neutrophil count falls below 
500cells/µl. patients with Absolute neutrophil count below 100cells/µl 
are at the greatest risk of fulminant lung infection.  
            Both quantitative and qualitative defects in neutrophil function 
have been demonstrated in hematological malignancies. Qualitative 
defects include defects in chemotaxis, phagocytosis, and absence of 
respiratory burst that accompanies phagocytosis. In addition to that 
chemotherapeutic agents including corticosteroids also decrease 
neutrophil function like phagocytosis and neutrophil migration (3). 
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            Granulocytopenia is a major determining factor for occurrence 
of infections especially involving lungs. A direct correlation has been 
demonstrated between the fall in Absolute neutrophil count and the 
increased incidence of infection. With Absolute neutrophil count below 
1000 cells/µl, there is a significant increase in incidence of respiratory 
infection and counts below 100cells/µl gram negative bacteremia and 
other fungal infections (15).  
             Greson and others found in their study that, neutropenia to be 
the major risk factor in occurrence of invasive pulmonary mycosis (16). 
Up to 60% 0f patients, with a neutrophil count of less than 1000 cells/µl 
develop lung infiltrates at sometime during the course of the disease, 
most commonly due to infectious etiology (17). 
            In patients with neutropenia commonest site of infection is 
Respiratory tract (18). 
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RADIOLOGICAL FINDINGS IN HEMTOLOGICAL 
MALIGNANCIES 
            Maj Michael F et al reviewed the inpatient records of 139 adult 
patients with leukemia and lymphoma to analyze the occurrence of 
bacterial and opportunistic infections and radiological abnormalities in 
such patients. 
             Fifty two (37%) of the 139 patients had no parenchymal 
infiltrates throughout their course in hospitalization. Twenty three 
patients of the 139 had only non parenchymal abnormalities like pleural 
effusion, mediastinal widening and hilar adenopathy. 
              He also observed in his study that during the course of 
chemotherapy parenchymal abnormalities occurred on 81 separate 
occasions in 70 patients. The roentgenographic pattern was that of local 
disease in 31 instances (38%) and that of diffuse disease in 50 instances 
(62%).  
               A cause for the disease process could be established in 90% 
(28/31) of local disease and in 80% (40/50) of diffuse disease. Of the 28 
episodes of local disease, in which infectious cause accounted for 82% 
(23/28), however an opportunistic organisms responsible only for 11% 
(3/28). In patients with diffuse disease in whom a cause could be 
25 
 
determined, infectious cause accounted for 35% (14/40). Ninety three 
percent (13/14) of diffuse disease caused by opportunistic organisms. 
             This study documented that bacterial and opportunistic 
infections are primary complications of acute leukemia. Infiltrates with 
local distribution are frequently bacterial infections and for diffuse 
distribution opportunistic organisms are frequent etiology (19).  
            M Von Eiff et al in his study documented that for both 
Aspergillus and Candida infections, bilateral diffuse pulmonary 
infiltrates is the commonest presentation in patients with acute 
leukemias (20). 
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BACTERIAL PNEUMONIA 
          Occurrences of Bacterial infections differ in frequency depending 
on underlying host immune defects.  
          Among which gram-negative bacteria like Pseudomonas 
aeroginosa and Klebsiella pneumoniae predominate in patients with 
hematological malignancy in which neutrophils are quantitatively or 
qualitatively impaired and chemotherapy induced neutropenia occur.  
          In patients with Multiple Myeloma or Chronic Lymphocytic 
Leukemia in whom abnormalities in the quantity or function of 
immunoglobulin are common and opsonisation impaired, encapsulated 
bacteria like Streptococcus pneumoniae and Hemophilus influenza are 
most common etiological agent for bacterial pneumonia. 
           Importantly in those with neutropenia, Staphylococcus aureus 
and Streptococcus viridians emerged as a most common pathogen for 
pneumonia as a result of prophylactic administration of antibiotics 
which act against gram negative bacteria. 
           Incidence of Staphylococcus aureus infection is more common in 
elder age group than in younger adults, and in those with risk factors for 
infection such as diabetes mellitus and alcohol intake.            
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           The term gram negative bacillary pneumonia refers to infections 
caused by members of two groups, the Enterobacteriaceae and 
pseudomonaceae. 
           At least 40% to 45% of Hospital Acquired Pneumonia in patients 
with leukemias is caused by Enterobacteriaceae such as Escherichia, 
Klebsiella, Enterobacter, Proteus, Serratia, Salmonella and citrobacter.  
          The Enterobacteriaceae normally colonize the digestive tract and 
pneumonia usually results from aspiration of oropharyngeal flora. 
Pneumonia caused by Enterobacteriaceae group of organisms is 
uncommon in healthy, non hospitalized individuals. The prevalence of 
oropharyngeal colonization by gram negative bacilli especially 
Enterobacteriaceae group is greatly increased by serious co-morbidities, 
immunocompromised state, hospitalization, risk of aspiration and 
antimicrobial use. Mortality due to Enterobacteriaceae pneumonia is 
25% to 50%. Presence of neutropenia, bacteremia and old age points to 
a poor prognosis in those patients infected with gram-negative bacilli. 
          Pseudomonas aeroginosa is a gram negative bacillus that is 
ubiquitous in environment and one of the most common opportunistic 
pathogen in humans.  
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          Among the anatomic location of Pseudomonas aeroginosa 
infection, the lung is the most common one and associated with highest 
mortality rate. The characteristic feature of pneumonia due to 
Pseudomonas aeroginosa is its occurrence in immunocompromised 
patients with hemorrhagic and necrotizing lung pathology. Patients in 
whom clinical manifestations of pneumonia exits along with a new 
pulmonary infiltrates, isolation of Pseudomonas aeroginosa from 
respiratory secretions, is often considered to be circumstantial evidence 
that Pseudomonas aeroginosa is the cause for pneumonia and it 
becomes the basis for initiation of anti pseudomonal antibiotic therapy. 
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FUNGAL PNEUMONIA 
         Among fungal infections, Aspergillus and Candida species are 
one of the most common pathogens, which constitute a major 
increasing cause for infection during the chemotherapy treatment of 
patients with hematological malignancies.  
          Diagnosis of invasive fungal infections during antemortam period 
is difficult one. The initial clinical and radiographic presentation of 
invasive fungal pneumonia is indistinguishable from those of other 
infectious pneumonia. In patients with severe neutropenia, clinical and 
radiological findings in the lungs are often absent. In patients with 
hematological malignancies thrombocytopenia or blood coagulation 
disorders are frequent, so biopsy is often contraindicated. High 
resolution computed tomography has been associated in the early 
diagnosis and management of opportunistic fungal pneumonia. 
           Livio Pagno et al in his study documented that the primary site 
of fungal infection are lungs (85%) in patients with leukemias and 
lymphomas. In 77% of patients with pulmonary filamentous fungal 
infection, chest x ray is a valuable diagnostic method, while CT scan 
being the most superior in detecting this in 95% of patients. Majority of 
infection with fungal pathogens occur in patients with hematological 
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malignancies, particularly Acute Myeloid Leukemia (AML). 
Aspergillus was the agent of filamentous fungal infection most 
frequently isolated in 76% 0f patients (296 cases). Aspergillus 
fumigates was the main agent among them (21). In patients with 
hematological malignancies Strong clinical or radiological evidence of 
fungal infection should be treated with full course of anti fungal 
therapy. 
          Candida pneumonia was first described in 1771 by Rosen Von 
Rosenstein. The most common predisposing factor proposed for 
Candida pneumonia is immunosuppression and neutropenia, mostly in 
malignant disease. Prolonged broad spectrum antibiotic therapy and 
prolonged corticosteroid therapy are also common predisposing factors 
for Candida infection. The positive sputum culture although not 
diagnostic for Candida, will arise a suspicion of Candida pneumonia. 
         Zab Mohsenifar and others in their study documented that the 
radiological findings of Candida pneumonia in patients with 
hematological malignancies. He found that 80% (16/20) of patients 
presented with diffuse infiltrates and 20% (4/20) 0f patients presented 
with focal infiltrates and concluded that diffuse infiltrates are the most 
common radiological findings in Candida pneumonia (22).  
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         Aspergillus is a saprophytic organism, which is ubiquitous in the 
environment. Respiratory tract is the commonest site of aspergillus 
infection. Depending essentially on the host‟s immunological status, 
Aspergillus species can give rise to various clinical manifestations. 
Invasion of pulmonary parenchyma by aspergillus species, especially in 
those patients with prolonged neutropenia leads to invasive pulmonary 
aspergillosis.  
 
TUBERCULOSIS IN HEMATOLOGICAL MALIGNANCIES 
        Tuberculosis infections are serious and life threatening 
complication in patients with hematological malignancies. Chances of 
reactivation of latent tuberculosis are more during chemotherapy with 
cytotoxic drugs and steroid for prolonged period (23).  
        Incidence of Tuberculosis in patients with hematological 
malignancies range between 2.1%to 2.6% (24). Clinically evident 
tuberculosis can antedate hematological malignancy, or both may 
present simultaneously or tuberculosis infection may develop after the 
treatment of the malignant disorders with chemotherapy. 
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        Tuberculosis occurs predominantly in males than females and in 
patients with Chronic myeloproliferative disorders, Acute myeloid 
leukemia and Myelodysplasia. The more intensive cytotoxic 
chemotherapy that is repeated courses of intravenous chemotherapy 
rather than oral chemotherapeutic agents, given for the primary 
hematological malignancies, leads to the earlier development of 
tuberculosis and the infection would be disseminated more likely. 
 
  
33 
 
PLEURAL EFFUSION IN HEMATOLOGICAL 
MALIGNANCIES 
         
Pleural effusion, either as isolated entity or associated with 
parenchymal lung infiltration, occur regularly in patients with 
hematological malignancies.  
        Michael G. Alexandrakis et al, in his review article about “ pleural 
effusion in  hematological malignancies” says that, the amount of 
pleural fluid accumulated in lymphomas may vary, ranging from little 
or no respiratory symptoms, and blunting of the costophrenic angle on 
chest radiography, to severe respiratory distress on clinical examination 
with opacification of a whole hemi thorax. The pleural fluid may appear 
serous or serosanguineous. In lymphomas, Pleural effusions are usually 
exudates. 
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He described about possible mechanisms for the formation of 
pleural effusions in patients with hematological malignancies include 
the following 
1. Pleural infiltration by the neoplasm with shedding of 
malignant cells into the pleural space 
2. Lymphomatous infiltration of the pulmonary and mediastinal 
lymph nodes by malignant cells leads to Lymphatic 
obstruction 
3. Obstruction of thoracic duct 
       Pleural involvement in Patients with Chronic Lymphocytic 
Leukemia (CLL), usually have a long standing diagnosis of CLL before 
the pleural effusion develops (25). 
      Jon Bais, MD et al discussed like that, most of the pleural effusions 
in which a thoracentesis was undertaken were moderate to large in size 
(87%) and were associated with parenchymal abnormalities (69%). 
Both bilateral effusions (62%) and unilateral effusions (38%) were 
subjected to thoracentesis. Exudates were documented in 83% of 
patients and 10% were tansudate and 7% were unclassified (26). 
  
35 
 
MATERIALS AND METHODS 
STUDY DESIGN 
             This is Prospective (Observational) study designed to find the 
pulmonary manifestations of patients with hematological malignancies 
in a tertiary care Institution. 
STUDY CENTER 
        Department of thoracic medicine, Rajiv Gandhi Government 
general Hospital & Madras Medical College, Chennai-3. 
       Department of Hematology, Rajiv Gandhi Government general 
Hospital & Madras Medical College, Chennai-3. 
STUDY DURATION 
          February 2012 to October 2012 
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STUDY POPULATION 
       Patients of >12 years of age with diagnosis of hematological 
malignancies, with respiratory symptoms or signs during examination 
or with radiological abnormalities were included in this study. 
       Proforma was designed and ethical committee clearance was 
obtained. A written informed consent was obtained from all patients 
included in this study after explaining in detail the nature and purpose 
of the study. 
INCLUSION CRITERIA     
1. age >12 years  
2. Any patient diagnosed with hematological malignancies 
presenting with respiratory symptoms /having respiratory signs 
during examination / with radiological  abnormalities  
EXCLUSION CRITERIA  
      1. Patients those who are not willing to give consent                  
     2. Patients too ill for a detailed work up were excluded 
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STUDY PROCEDURE 
       124 inpatients in the Hematology & Thoracic medicine department 
with respiratory manifestations who satisfied the above inclusion & 
exclusion criteria were enrolled in this study. After obtaining informed 
consent from them they were examined clinically after a detailed 
history.  
        These patients were subjected to various diagnostic tests including 
 Complete blood count 
 Random blood sugar 
 Renal function test 
 Liver function test 
 HIV testing 
 Sputum for Acid Fast Bacilli 
 Sputum for Gram stain 
 Sputum for aerobic bacterial culture 
 Sputum for fungal smear &culture 
 Sputum for malignant cells 
 Chest X ray 
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Patients with pleural effusion in chest x ray were subjected to 
diagnostic thoracentesis, and the pleural fluid has been sent for  
 Biochemical analysis like sugar, protein and lactate 
dehydrogenase 
 Cell count 
 Cytology for malignant cells 
 Acid fast stain 
 Gram stain & aerobic bacterial culture 
 Fungal smear & fungal culture. 
In patients with abnormal roentgenographic findings were 
subjected to CT chest/ high resolution CT chest. 
 
GRAM STAIN TECHNIQUE 
        A new unscratched slide was selected. A loopful of sputum had 
been transferred to the surface of a clean glass slide with a wooden stick 
and was smeared over a small area. Then the smear had been allowed to 
air dry. The air dried film was fixed by passing it briefly through the 
Bunsen flame two or three times without exposing the dried smear 
directly to the flame. The slide should not be hot as to be uncomfortable 
to the touch. Then slide was flooded with crystal violet solution for up 
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to one minute, and washed briefly with tap water (not over 5 seconds) , 
again the slide was flooded with Gram‟s Iodine solution and allowed to 
act (as a mordant) for about one minute. The slide was washed in 
running tap water. Excess water had been removed from slide with 
blotting paper, so that alcohol used for decolorization was not diluted. 
The slide then flooded with 95% alcohol for 10 seconds and washed 
again with tap water (smear that are excessively thick may require 
longer decolorization time. Decolorization procedure is the most 
sensitive and variable step of grams stain technique, and it requires 
experience to know just how much to decolorize the slide). The slide 
was stained with Safranin solution, which acts as a counter stain and 
allowed to act for 30 seconds. The slide again washed in tap water and 
dried with bibulous paper. Slide was examined under oil immersion 
lens. 
BACTERIAL CULTURE 
       Fresh sputum collected in a sterile container with screw cap had 
been sent for examination. Care had been taken that the specimen is 
sputum and not saliva. Examination of Gram stain, with number of 
epithelial cells and polymorphonuclear leukocytes had been noted. 
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Blood agar, Chocolate agar and Mac conkeys agar were the culture 
medium has been used for aerobic bacterial culture. 
FUNGAL SMEAR & FUNGAL CULTURE 
      The laboratory diagnosis of fungus infection was made by 
microscopic examination of sputum, which was usually examined as 
wet mounts after treatment with 10% potassium hydroxide. Potassium 
hydroxide digests cells and other tissue materials, and enabling the 
fungus elements to be seen clearly. First morning sputum was collected 
for fungal culture, before that procedure patient had been instructed to 
rinse his mouth, collect sputum resulting from a deep cough and 
expectorate the sputum immediately into a sputum collection container, 
without holding sputum in the mouth. The commonest culture media 
used in this study was Sabouraud‟s glucose agar. Identification was 
based on morphology of the fungus and of its colony. Sensitivity of the 
organisms to antifungal drugs was not done in our study. 
ZIEHL- NEELSON STAINING METHOD 
        A new unscratched slide was selected. The slide was labeled with 
the laboratory serial number using a diamond marking pencil. Smear 
was made from the yellow muco-purulant portion of the sputum sample 
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using a loop. Smear was spread evenly, about the size of 2cm x 2cm, 
smear was made neither thick nor too thin. Then slide was allowed to 
air dry for 15 to 30 minutes. The smear was then fixed by passing it 
over a flame 3 to 5 times, for 3 to 4 seconds each time. 1% Carbol 
fuschin, primary stain was poured to cover the entire slide. After which 
the slide was then gently warmed with the Carbol fuschin on it, until 
vapors arose. Care has been taken not to let it boil. After boiling Carbol 
fuschin was left on the slide for five minutes. Then the slide was rinsed 
under tap water until all the free Carbol fuschin stain was washed away. 
For decolorizing the primary stain, 25% Sulphuric acid was then poured 
onto the slide. The slide was left to stand for 2 to 4 minutes. Then it was 
gently rinsed under tap water, and then slide was tilted to drain off the 
water.    
        0.1% Methylene was poured onto the slide, then left on the slide 
for 30 seconds. The slide was then gently rinsed under tap water and 
allowed to dry. The slide was then examined under microscope using 
the 40x lens to select a suitable area then examined using 100 x lenses 
with a drop of immersion oil (27). 
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DIAGNOSTIC THORACENTESIS  
       Once the site of thoracentesis was identified, the site was marked 
by exerting pressure using the end of a ballpoint pen with the tip 
retracted. Then the skin surrounding the proposed site over an area 
extending at least 4 inch in all directions was cleansed thoroughly with 
an antiseptic solution. By using a short 25-gauge needle, the skin was 
anaesthetized by injecting enough lignocaine, around 0.5 ml, to raise a 
small wheal in skin. The small 25-gauge needle is then replaced by a 
1.5 inch long 22-gauge needle. This long needle was inserted to the 
periosteum of the rib underlying the proposed thoracentesis site, and the 
needle was moved up and over the rib with frequent injection of small 
amounts of lignocaine. Once this needle was superior to the rib, then it 
was slowly advanced toward the pleural space with frequent aspiration, 
followed by injection of lignocaine 1 to 2 mm. As soon as the pleural 
fluid was aspirated through this needle into the syringe containing 
lignocaine; the needle was withdrawn from the pleural space and 
reattached to 20 ml syringe. The same long 22-gauge needle was 
reintroduced along the same tract with constant aspiration until pleural 
fluid was obtained. Once pleural fluid was obtained aspiration was then 
continued until the syringe was filled. After that, needle was withdrawn, 
43 
 
and the procedure was finished. Aspirated fluid was then sent for 
Biochemical analysis (protein, glucose and lactate dehydrogenase), cell 
count, Gram‟s stain, aerobic bacterial culture, acid fast stain, fungal 
smear and culture, and cytology for malignant cells. 
 
DEFINITIONS AND CRITERIAS 
FEVER 
       Fever was defined as single reading of oral temperature ≥ 101 F 
recorded or two values >100.4 F recorded at least one hour apart, and it 
was unrelated to blood product transfusions or chemotherapy drug 
administration (2). 
NEUTROPENIA 
        Neutropenia is defined as an absolute neutrophil count 
(polymorphonuclear cells plus band forms) of 1000/µl or less (3). 
RADIOLOGICAL FINDINGS 
       FOCAL- if there is lobar or segmental involvement 
       DIFFUSE- all other parenchymal abnormalities (28) 
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UPPER RESPIRATORY TRACT INFECTION 
        The International Classification of health problems in primary 
health care defines “upper respiratory tract infections” as acute 
inflammation of nasal or pharyngeal mucosa in the absence of other 
specifically defined respiratory infection. It consist of nasopharyngitis 
(common cold), pharyngitis, otitis media, sinusitis, laryngitis and acute 
bronchitis (29). 
ACUTE BRONCHITIS   
         For the diagnosis of acute bronchitis at least two of the following 
symptom and sign should be present: increased frequency and severity 
of cough, new or increased sputum production, fever (temperature 
≥38⁰C), and burning substernal chest discomfort with coughing or deep 
inspiration. Radiologic evidence of pneumonia excluded the diagnosis 
of acute bronchitis (29). 
 
PNEUMONIA 
        Pneumonia is defined as inflammation and consolidation of lung 
tissue due to an infectious agent and characterized by radiographic 
infiltrate. Pneumonia can be classified as follows: 
45 
 
          Community acquired pneumonia 
          Nosocomial pneumonia 
          Ventilator associated pneumonia 
          Hospital acquired pneumonia 
          Health care associated pneumonia          
COMMUNITY ACQUIRED PNEUMONIA 
       Pneumonia that develops outside the hospital is considered 
Community acquired pneumonia (CAP) 
HOSPITAL ACQUIRED PNEUMONIA (HAP) 
      Pneumonia that is neither present nor incubating at the time of 
admission and occurring after 48 hours of admission. 
VENTILATOR ASSOCIATED PNEUMONIA 
Complicates Intubation Process 
Early onset-occurring VAP in 48-72 hrs 
Late onset- occurring VAP after 72 hrs 
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HEALTH CARE ASSOCIATED PNEUMONIA 
 Patients with pneumonia developing in 2 to 90 days of 
hospitalization 
 Recent exposure to hemodialysis, I.V antibiotics chemotherapy, 
wound care 
 Resident of nursing home 
 Person may be residing in a community but he was infected with 
organism similar to HAP. 
OPPORTUNISTIC INFECTIONS 
       Those caused by Fungus, Cytomegalovirus, Parasitic disease, or 
Mycobacterium. (19) 
BACTERIAL PNEUMONIA 
 Productive cough 
 Lung infiltration on chest radiography  
 Fever ≥38.4⁰ c 
With one of the following 
1. Positive blood or pleural fluid or sputum culture 
2. PSB culture showing ≥ 10³ CFU/ml 
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3. Quantitative BAL culture showing ≥10⁵ CFU/ml 
4. Complete resolution of clinical or radiological signs with a 
course of antibiotic therapy 
 
FUNGAL PNEUMONIA 
 Fever resistant to antibiotic therapy for more than 5 days 
 Appearance of new pulmonary infiltrates  
 Histological demonstration of pulmonary invasive disease or 
positive cultures in sputum or bronchoscopic specimen (20). 
 
PULMONARY TUBERCULOSIS 
        . Diagnosis by microscopic examination of a sputum smear 
prepared by ziehl- neelson staining method detecting the acid fast 
bacilli. 
LIGHT’S CRITERIA 
         This is the first step to determine whether the pleural effusion is a 
transudate or exudate. Light‟s criteria were used to differentiate 
exudative pleural effusion from transudative pleural effusion. Exudative 
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pleural effusion meets at least one of the following criteria, whereas 
transudative pleural effusions meet none: 
 Pleural fluid protein divided by serum protein greater than 0.5 
 Pleural fluid LDH divided by serum LDH greater than 0.6 
 Pleural fluid LDH greater than two thirds of the upper limit of 
normal serum LDH 
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RESULTS 
 
        In this study 124 patients with hematological malignancies were 
enrolled. All the patients were subjected to microbiological and 
radiological investigations. Results from those investigations were 
analyzed statistically, and the results of which were as follows. 
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DEMOGRAPHY 
AGE AND SEX DISTRIBUTION 
TABLE 1: 
SEX 
AGE DISTRIBUTION 
Total 
≤ 15 
Yrs 
16 - 30 
yrs 
31 - 45 
yrs 
46 - 60 
yrs 
> 60 
yrs 
MALE 4 18 8 10 2 42 
FEMALE  - 36 27 16 3 82 
Total 4 54 35 26 5 124 
        
      The highest incidence of hematological malignancies was noted in 
the 16-30 years age group. Among all age groups, there was a female 
preponderance. 
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HEMATOLOGICAL MALIGNANCIES 
 
TABLE 2: 
DIAGNOSIS MALE FEMALE 
AML 21 30 
CML 0 8 
ALL 17 30 
CLL 4 13 
HODGKIN 0 1 
TOTAL 42 82 
 
 
      This table shows the distribution of hematological malignancies in 
124 patients, in which 51 patients had Acute myeloid leukemia (AML), 
8 patients had Chronic myeloid leukemia (CML), 47 patients had Acute 
lymphoblastic leukemia (ALL), 17 patients had Chronic lymphoid 
leukemia (CLL) and one patient had Hodgkin lymphoma. 
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CLINICAL FEATURES 
TABLE 3: 
PRESENTING SYMPTOMS & SIGNS 
SYMPTOMS & 
SIGNS TOTAL 
PERCENTAGE 
(N=124) 
     SYMPTOMS 
         Cough 
  
110 88.70 
         Expectoration 107 86.29 
         Breathlessness 66 53.22 
         Chest pain 18 14.51 
         Hemoptysis 20 16.12 
         Fever 90 72.58 
     SIGNS 
        Tachypnea 
  
70 56.45 
        Wheeze 30 24.19 
        Crackles 38 30.64 
 
      This table shows that cough and expectoration were the common 
symptoms followed by fever. 
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RADIOLOGICAL FINDINGS 
 
       The radiological investigations were done in all 124 patients after 
obtaining informed written consent, findings observed in Radiography 
were 60 patients had no abnormal defect, 6 patients had pleural 
effusion, 58 patients had parenchymal infiltrates in them 31 had focal 
and 27 had diffuse infiltrate. 
TABLE 4: 
RADIOLOGY TOTAL 
PERCENTAGE 
(N=124) 
NAD 60 
 
48.38 
Focal infiltrates 31 
 
29.03 
Diffuse infiltrates 27 
 
17.74 
Pleural effusion 6 
 
4.83 
Total 124 
 
100 
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RADIOLOGICAL FINDINGS 
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RADIOLOGICAL FINDINGS IN HEMATOLOGICAL 
MALIGNANCIES 
TABLE 5: 
Hematological 
Malignancies 
RADIOLOGY 
Total 
NAD 
Focal 
infiltrates 
Diffuse 
infiltrates 
Pleural 
effusion 
AML 30 12 9  - 51 
CML 8  -  -  - 8 
ALL 18 18 11  - 47 
CLL 4 5 2  6 17 
HODGKINS -  1  -  - 1 
Total 60 36 22 6 124 
 
       This table shows the distribution of radiological findings in 
hematological malignancies, among 58 patients with parenchymal 
infiltrates, 50 patients were belonged to Acute leukemia (21 AML& 29 
ALL) and 6 patients with pleural effusion were belonged to Chronic 
lymphoid leukemia (CLL). 
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RADIOLOGICAL FINDINGS IN HEMATOLOGICAL 
MALIGNANCIES 
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RESPIRATORY DIAGNOSIS 
 
TABLE 6: 
RESPIRATORY 
DIAGNOSIS TOTAL 
PERCENTAGE 
(N=124) 
URI/ACUTE 
BRONCHITIS 60 48.38 
Bacterial Pneumonia 28 22.58 
Fungal Pneumonia 14 11.29 
Pleural effusion 6 4.83 
Tuberculosis 1 0.80 
 
         This table shows that Upper respiratory tract /acute bronchitis is 
the common pulmonary abnormalities associated with hematological 
malignancies. 28 (22.58%) patients had bacterial pneumonia, 14 (11%) 
patients had fungal pneumonia, 6 (5%) patients had exudative pleural 
effusion and one patient was infected with Mycobacterium tuberculosis.   
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NEUTROPHIL COUNT AND DIAGNOSIS 
TABLE 7: 
NEUTROPHIL 
COUNT 
CLINICAL DIAGNOSIS 
URI/ACUTE 
BRONCHITIS 
Infection 
Bacterial 
Pneumonia 
Infection 
Fungal 
Pneumonia 
Pleural 
effusion 
Tuberculosis 
< 100 / µL - -  -  -  -  
100 - 250 / µL  - 2 3  -  - 
250 - 500 / µL 1 4 5  -  - 
500 - 1000 / µL 7 18 5  -  - 
> 1000  / µL 52 4 1 6 1 
Total 60 28 14 6 1 
 
       This table shows the distribution of infection in hematological 
malignancies in relation with neutrophil count. In patients with 
neutrophil count <1000/µl, there was a significant increase in 
occurrence of bacterial infection, and there was a significant increase in 
occurrence of fungal infection when the neutrophil count falls below 
500/ µl. 
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MICROBIOLOGICAL SPECTRUM 
 
TABLE 8: 
ORGANISM TOTAL PERCENTAGE (N=124) 
NO GROWTH 81 65.32 
BACTERIAL 29  
   GRAM POSITIVE 4  
        Staphylococcus 
aureus 
3 2.41 
        non Hemophilus     
                streptococci 
1 0.80 
   GRAM NEGATIVE 24  
        Pseudomonas  
             aeroginosa 
10 8.06 
       Klebsiella pneumoniae 9 7.25 
       Escherichia coli 5 4.03 
   Mycobacterium 
         tuberculosis 
1 0.80 
FUNGAL 14  
      Aspergillus fumigates 5 4.03 
      Aspergillus flavus 2 1.61 
      Candida albicans 4 3.22 
Candida non albicans 3 2.41 
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In this study, sputum cultures were done in all 124 patients. 
Findings observed were 81 patients had no growth in culture. 29 
patients had bacterial growth among them Gram-negative organisms 
showed more predominance. 14 patients had fungal growth, with more 
predominance towards Aspergillus fumigates. 
MICROBIOLOGICAL SPECTRUM 
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RESPIRATORY DIAGNOSIS IN RELATION WITH DURATION 
OF CHEMOTHERAPY 
TABLE 9: 
Duration of 
chemotheraphy 
CLINICAL DIAGNOSIS 
URI/ACUTE 
BRONCHITIS 
Infection 
Bacterial 
Pneumonia 
Infection 
Fungal 
Pneumonia 
Pleural 
effusion 
Tubercluosis 
No 
chemotheraphy 
6 5 2 1 1 
< 1 mth 2 1 2 - - 
1 - 6 mths 21 10 5 - - 
6 - 12 mths 22 10 3 3 - 
> 12 mths 9 2 2 2 - 
Total 60 28 14 6 1 
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     This line diagram shows, more infections were seen after prolonged 
chemotherapy in patients with hematological malignancies. 
 
RESPIRATORY DIAGNOSIS IN RELATION WITH DURATION 
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RESPIRATORY DIAGNOSIS IN 
HEMATOLOGICAL MALIGNANCIES 
TABLE 10: 
Hematological 
Malignancies 
CLINICAL DIAGNOSIS 
Total 
URI/ACUTE 
BRONCHITIS 
Infection 
Bacterial 
Pneumonia 
Infection 
Fungal 
Pneumonia 
Pleural 
effusion 
Tuberculosis 
AML/ALL 48 25 14     87 
CML/CLL 12 3   6   21 
Total 60 28 14 6 0 108 
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RADIOLOGICAL FINDINGS & RESPIRATORY CONDITION 
 
TABLE 11: 
 
CLINICAL 
DIAGNOSIS 
RADIOLOGY 
Total 
NAD 
Focal 
infiltrates 
Diffuse 
infiltrates 
Pleural 
effusion 
URI/ACUTE 
BRONCHITIS 
60 -  -  -  60 
Infection Bacterial 
Pneumonia 
 - 25 3  - 28 
Infection Fungal 
Pneumonia 
 - -  14  - 14 
Pleural effusion  -  - -  6 6 
Tuberculosis  - 1  -  - 1 
Total 60 26 17 6 109 
 
      A cause for the disease process was established in 26 of 31 patients 
with focal infiltrates and 17 of 27 patients with diffuse infiltrates. The 
above table shows the causes. Of the 26 patients with focal infiltrate in 
which the cause could be established, 25 patients had bacterial infection 
and one patient had tuberculous infection. In contrast to the findings in 
the patients with focal infiltrate, 14 of 17 infections were caused by 
fungal organisms. 
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RESPIRATORY DIAGNOSIS IN HEMATOLOGICAL 
MALIGNANCIES 
TABLE 12: 
Hematological 
Malignancies 
CLINICAL DIAGNOSIS 
URI/ACUTE 
BRONCHITIS 
Infection 
Bacterial 
Pneumonia 
Infection 
Fungal 
Pneumonia 
Pleural 
effusion 
Tuberculosis 
AML 30 11 7 
  
CML 8 
    
ALL 18 14 7 
  
CLL 4 3 
 
6 
 
HODGKINS 
    
1 
Total 60 28 14 6 1 
 
       From this table we observed that out of 28 cases of bacterial 
pneumonias, 25 cases were occurred in acute leukemias and all cases of 
fungal pneumonias were occurred in acute leukemias. All 6 cases of 
exudative pleural effusion were occurred in chronic lymphocytic 
leukemia. Only one case of tuberculosis was noted, in Hodgkin 
lymphoma. 
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DISCUSSION 
 
        Hematological malignancies are a diverse group of disorders, in 
which various pulmonary manifestations are noted. Infections are 
common causes for increased morbidity and mortality in those patients 
with leukemia and lymphoma, among which lung is the commonest site 
(1).  
        Among hematological malignancies, incidences of infections are 
more common with Acute leukemia, that is Acute myeloid leukemia & 
Acute lymphoblastic leukemia. 
         A Rano et al in his study, says that infections by bacterial 
organisms mainly those caused by Pseudomonas aeroginosa and 
Staphylococcus aureus were the most frequent infections, followed by 
fungal organisms, mainly Aspergillus species were the second most 
common infectious cause of pulmonary infiltrates (4). 
        The degree of neutropenia either as a consequence of primary 
hematological malignancy or therapy is directly related to the incidence 
of serious bacterial and fungal pneumonias. There is a steady increase 
in the occurrence of infection with Absolute neutrophil count below 
1000cells/µl.  
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      Gerson and associates found Granulocytopenia to be the single most 
important predisposing factor for development of pulmonary infections 
in patients with leukemias and lymphomas. The incidence of infection 
in hematological neoplasms inversely proportional to the Absolute 
neutrophil count (16, 18). 
       Maj Michael F. Tenholder et al in his study about “pulmonary 
infiltrates in leukemia” says that, in 82% of patients presented with 
focal disease due to infection, the infection were primarily bacterial in 
origin in 86% of patients, with only 13% of patients with focal 
infiltrates were infected by opportunistic organisms. The episodes of 
diffuse pulmonary infiltrates occur during treatment were infectious 
only in 35% of patients. In contrast to the group with focal disease, 93% 
of patients were infected with opportunistic organisms. 
       In our study, 124 patients were included, among which 79% 
patients were belonged to Acute leukemia (Acute myeloid leukemia 
41.12% & Acute lymphoblastic leukemia 37.90%).  
       The radiological findings observed in our study were, 60 patients 
had no abnormal defect, 6 patients had pleural effusion, and 58 patients 
had parenchymal infiltrates in them 31 had focal and 27 had diffuse 
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infiltrates. Among 58 patients with parenchymal infiltrates 50 (86%) 
patients were belonged to acute leukemias. Of the 31 patients with focal 
infiltrates the cause was established in 26 patients. Of the 26 patients 
with focal infiltrate in which the cause could be established, 25 patients 
had bacterial infection and one patient had tuberculous infection. 
Among 27 patients with diffuse infiltration etiology was identified in 17 
patients, of whom 14 patients had fungal infection and in 3 patients 
bacterial pathogen had been isolated. 
       In patients with neutrophil count <1000/µl, there was a steady 
increase in incidence of bacterial infection, and there was a marked 
increase in incidence of fungal infection when the neutrophil count falls 
below 500/µl. 
      The sputum culture reports were positive more for bacterial 
organisms followed by fungal organisms. Among them Pseudomonas 
aeroginosa was the predominant organism, followed by Klebsiella 
pneumoniae and Aspergillus fumigates.  
     In our study, Upper respiratory tract infection and Acute bronchitis 
were the most common respiratory diagnosis, in patients with 
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hematological malignancies, followed by bacterial and fungal 
pneumonias. Tuberculosis was reported in only one patient.  
      Incidences of both bacterial and fungal were predominantly seen in 
Acute leukemias. 
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CONCLUSION 
1. Pulmonary infections are common cause for increased 
morbidity and mortality in patients with hematological 
malignancies. 
2. Upper respiratory tract infection and acute bronchitis are the 
most common associated respiratory diagnosis in patients with 
hematological malignancies    
3.   Neutropenia is the major factor in determining the 
development of pulmonary infections.     
4. Bacterial pneumonia predominantly present as focal infiltrates 
and fungal pneumonia as diffuse infiltrates.                       
5. Pulmonary infections are predominantly caused by gram-
negative bacteria (Pseudomonas aeroginosa & Klebsiella 
pneumoniae) followed by fungal (Aspergillus fumigates) 
organisms. 
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INSTITUTE OF THORACIC MEDICINE 
MMC & RGGGH, CHENNAI-3 
“EVALUATION OF PULMONARY MANIFESTATIONS 
IN HEMATOLOGICAL MALIGNANCIES” 
PROFORMA 
NAME  
AGE  
SEX  
I.P NO.  
OCCUPATION  
 
CLINICAL DATA: 
 HEMATOLOGICAL  MALIGNANCY  TYPE 
 TIME SINCE DIAGNOSIS 
 TYPE TREATMENT FOR MALIGNANCY 
            1. NONE 
           2. ON CHEMOTHERAPY   -DRUG AND 
DURATION 
           3. OFF CHEMOTHERAPY -DURATION 
           4. OTHER DRUGS 
                    5. TRANSFUSION HISTORY 
 
 
 
 RESPIRATORY SYMPTOMS 
             COUGH 
             EXPECTORATION   
                 BREATHLESSNESS 
             HEMOPTYSIS 
            CHEST PAIN  
            FEVER 
PAST HISTORY: 
              KNOWN CASE OF BRONCHIAL ASTHMA/ 
COPD 
              PRIOR TREATMENT FOR PULMONARY 
TUBERCULOSIS 
              DIABETES MELLITUS  
    
PERSONAL HISTORY:    SMOKER 
                                            ALCOHOL USE 
CLINICAL EXAMINATION: 
   Conscious- 
   Oriented- 
   Dyspnea- 
 
 
                           Respiratory rate- 
   Anemia- 
   Jaundice- 
   Pedal edema- 
   Cyanosis- 
   Clubbing- 
VITAL SIGNS: 
   Pulse- 
   BP- 
   RR- 
SYSTEMIC EXAMINATION: 
   CVS:  S1S2- 
                                            Murmurs- 
                           RS: 
    B/L Air entry- 
    NVBS- 
    Added Sounds- 
   P/A: 
    Organomegaly- 
    Free fluid- 
 
 
 
INVESTIGATIONS: 
Complete Blood Count: 
     
Total count  
Differential Count  
ESR  
Hemoglobin  
Packed Cell Volume  
Platelet Count  
 
Renal Function Test: 
Blood Sugar  
Blood Urea  
Serum Creatinine  
Serum Sodium  
Serum Potassium  
Liver Function Test: 
Total Bilirubin  
SGOT  
SGPT  
SAP  
Total Proteins  
Serum Albumin  
     
ICTC: 
SPO2:  
 
 
 
 
SPUTUM FOR    GRAM STAIN 
                             NON TUBERCULOUS CULTURE 
                             ACID FAST STAIN 
                            FUNGAL SMEAR AND CULTURE 
                             CYTOLOGY 
BLOOD CULTURE (ENTERIC AND NON ENTERIC) 
PLEURAL FLUID ANALYSIS: 
                            SUGAR 
                           PROTEIN 
                           LDH 
                           CELL COUNT 
                           CYTOLOGY 
                          AFB 
                         GRAM STAIN 
                          NON TUBERCULOUS CULTURE  
CHEST X RAY: 
CT/HRCT CHEST: 
 
 
 
 
 
INFORMATION SHEET 
 Your specimen has been accepted. 
 We are conducting a study on pulmonary manifestations in 
haematological malignancies patients attending Government 
 General Hospital, Chennai and for that your specimen may be 
valuable to us. 
 The purpose of this study is to diagnose certain pulmonary 
manifestations in haematological malignancies easily with the help 
of certain special tests. 
 We are selecting certain cases and if your specimen is found 
eligible, we may be using your specimen to perform extra tests and 
special studies which in any way do not affect your final report or 
management. 
 The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information 
will be shared. 
 Taking part in this study is voluntary. You are free to decide whether 
to participate in this study or to withdraw at any time; your decision 
will not result in any loss of benefits to which you are otherwise 
entitled. 
 The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
Signature of investigator                                Signature of participant 
 
Date : 
 
 
 
 
 
PATIENT CONSENT FORM    
 
 
Title of the study: EVALUATION OF PULMONARY MANIFESTATIONS IN  
                                 HEMATOLOGICAL MALIGNANCIES 
         
 
Name of the Participant: 
______________________________________________________. 
 
Name of the Principal (Co-Investigator): Dr.G.RAVI KUMAR 
 
Name of the Institution: Madras medical college and Rajiv Gandhi 
Government General 
                                           Hospital, Chennai-3 
 
 
Documentation of the informed consent 
 
 
I _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been 
answered. I , hereby give my consent to be included as a participant in 
“EVALUATION OF PULMONARY MANIFESTATIONS IN HEMATOLOGICAL 
MALIGNANCIES” 
1. I have read and understood this consent form and the information provided to 
me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the    
    past ________ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this 
study.* 
7. I agree to cooperate with the investigator and I will inform him/her immediately if 
I suffer 
    unusual symptoms. * 
8. I have not participated in any research study within the past 
_________month(s). * 
9. I have not donated blood within the past _______ months—Add if the study 
involves     extensive blood sampling. * 
10. I am aware of the fact that I can opt out of the study at any time without having 
to give any  
      reason and this will not affect my future treatment in this hospital. * 
11. I am also aware that the investigator may terminate my participation in the 
study at any time,  
      for any reason, without my consent. * 
12. I hereby give permission to the investigators to release the information 
obtained from me as  
 
 
      Result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies,  
      and IEC. I understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are 
publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study.  
 
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given 
a copy of this consent document 
 
 
 
Name and signature / thumb impression of the participant (or legal 
representative if  participant incompetents) 
 
 
Name ________________Signature_________________ 
Date________________ 
 
 
 
 
 
Name and Signature of the investigator or his representative obtaining 
consent: 
 
Name ___________________ Signature_________________ 
Date________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
